HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
DA 1131
structure in first source
Also Known As:
2-(3-methanesulfonylamino-1-propenyl)pyrrolidin-4-ylthiol-6-(1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylic acid; DA-1131
Networked:
6
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Amides: 2428
Lactams: 2198
beta-Lactams: 2386
Carbapenems: 4837
DA 1131: 6
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
beta-Lactams: 2386
Carbapenems: 4837
DA 1131: 6
Related Diseases
1.
Body Weight (Weight, Body)
05/01/1998 - "
These allometric equations were extrapolated to predict the CI and Vss for DA-1131 in humans based on 70 kg body weight.
"
05/01/1998 - "
The total body clearance (CI), renal clearance (CIr), and apparent volume of distribution at steady state (Vss) of DA-1131, a new carbapenem, after intravenous (iv) administration of the drug, 50 mg kg-1, to mice, rats, rabbits, and dogs were analysed as a function of species body weight (W) using the allometric equation for interspecies scaling, and were used to predict these parameters in humans.
"
01/01/1999 - "
The effects of probenecid, an anion transport inhibitor, on the renal excretion mechanism of a new anionic carbapenem, DA-1131, were investigated after a 1-min intravenous infusion of DA-1131 at 100 mg/kg of body weight to rabbits and 50 mg/kg to rats with or without probenecid at 50 mg/kg for both species.
"
05/01/1998 - "
Because the physiological changes that occur in patients with acute renal failure could alter the pharmacokinetics of the drugs used to treat the disease, the pharmacokinetics of DA-1131, a new carbapenem antibiotic, were investigated after 1-min intravenous administration of the drug (50 mg/kg of body weight) to control rats and rats with uranyl nitrate-induced acute renal failure (U-ARF rats).
"
2.
Acute Kidney Injury (Acute Renal Failure)
05/01/1998 - "
Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with uranyl nitrate-induced acute renal failure.
"
05/01/1998 - "
Because the physiological changes that occur in patients with acute renal failure could alter the pharmacokinetics of the drugs used to treat the disease, the pharmacokinetics of DA-1131, a new carbapenem antibiotic, were investigated after 1-min intravenous administration of the drug (50 mg/kg of body weight) to control rats and rats with uranyl nitrate-induced acute renal failure (U-ARF rats).
"
3.
Necrosis
04/01/1999 - "
Extensive tubular necrosis was observed without betamipron but the necrosis was not observed with betamipron at 8 h after intravenous administration of DA-1131 based on kidney microscopy.
"
4.
Hypertension (High Blood Pressure)
06/01/1999 - "
The pharmacokinetics of a new carbapenem, DA-1131, were compared after i.v. administration of the drug, 50 mg/kg, to spontaneously hypertensive rats (SHRs) at 16 weeks of age (an animal model for human primary hypertension) and at 6 weeks of age (corresponding to the early phase of the development of hypertension, at which time blood pressure remains within the normotensive range) and their respective age-matched control normotensive Kyoto-Wistar rats (KW rats), and deoxycorticosterone acetate-salt-induced hypertensive rats at 16 weeks of age (an animal model for human secondary hypertension) and their age-matched control Sprague-Dawley rats.
"
5.
Diabetes Mellitus
07/01/1998 - "
Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with alloxan-induced diabetes mellitus.
"
07/01/1998 - "
Because physiological changes occurring in diabetes patients could alter the pharmacokinetics of drugs used to treat the disease, the pharmacokinetics and tissue distribution of DA-1131, a new carbapenem antibiotic, were investigated after 1-min intravenous (i.v.) administration of the drug, 50 mg kg-1, to control and alloxan-induced diabetes mellitus (AIDM) rats.
"
Related Drugs and Biologics
1.
Carbapenems (Carbapenem Antibiotics)
2.
Anti-Bacterial Agents (Antibiotics)
3.
Uranyl Nitrate
4.
Salts
5.
Probenecid (Benemid)
6.
Desoxycorticosterone (Deoxycorticosterone)
7.
Anions
8.
Alloxan
9.
Acetates (Acetic Acid Esters)
10.
N-benzoylalanine (betamipron)
Related Therapies and Procedures
1.
Intravenous Administration
2.
Intravenous Infusions